| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director | 10% Owner +3 more
10 companies
Fairmount Funds Management LLC is a Director at COGT, with reported holdings spanning 10 companies. Recent filings cover 22 purchases and 4 sales. Those positions are worth an estimated $489.6M at current prices.
Our model assigns Fairmount Funds Management LLC a strong insider score of 74/100, based on 18 past trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +53.5%.
Fairmount Funds Management LLC's largest disclosed position is in COGT as Director, worth about $190.7M. The recent filings there lean toward selling, a net 5,722,223 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2025 | COGT Cogent Biosciences, Inc. | Director | Buy | 2,777,777 | $9.00 | $24,999,993.00 | +44.6% | +43.6% | +258.2% | |
| Sep 16, 2024 | ZBIO Zenas Biopharma, Inc. | Director | Buy | 300,000 | $17.00 | $5,100,000.00 | +23.0% | -51.2% | +1.5% | |
| Sep 13, 2024 | VRDN Viridian Therapeutics, Inc.\de | Director, 10% Owner | Buy | 1,600,000 | $18.75 | $30,000,000.00 | +86.7% | -18.4% | -14.5% | |
| Jan 22, 2024 | VRDN Viridian Therapeutics, Inc.\de | Director, 10% Owner, See Remarks | Buy | 476,190 | $21.00 | $9,999,990.00 | +34.9% | -28.5% | -7.9% | |
| Sep 29, 2023 | DNTH Dianthus Therapeutics, Inc. /de/ | Director, 10% Owner | Buy | 24,670 | $13.63 | $336,252.10 | +1.3% | -25.9% | +99.3% | |
| Sep 26, 2023 | DNTH Dianthus Therapeutics, Inc. /de/ | Director, 10% Owner | Buy | 30,000 | $13.15 | $394,500.00 | +1.6% | -12.7% | +102.5% | |
| Sep 19, 2023 | DNTH Dianthus Therapeutics, Inc. /de/ | Director, 10% Owner | Buy | 30,000 | $13.20 | $396,000.00 | +1.6% | -49.0% | +97.1% | |
| Sep 13, 2023 | DNTH Dianthus Therapeutics, Inc. /de/ | Director, 10% Owner | Buy | 24,254 | $11.20 | $271,679.87 | +1.3% | -37.5% | +122.3% | |
| Jul 13, 2023 | APGE Apogee Therapeutics, Inc. | Director | Buy | 2,941,176 | $17.00 | $49,999,992.00 | -143.6% | -4.1% | +126.2% | |
| Jun 9, 2023 | COGT Cogent Biosciences, Inc. | 10% Owner, See Remarks | Buy | 800,000 | $12.00 | $9,600,000.00 | +32.4% | +0.5% | -30.1% |